Our results show that TMZ with other chemotherapeutic agents, regardless the type and number of added drugs, produce a significantly better outcome (reduced recurrence interval) in glioblastoma without TP53 expression or non-methylated MGMT promotor. Here, TP53 is linked to glioblastoma.